Successful treatment of musk antibody-positive myasthenia gravis with rituximab

被引：79

作者：

Hain, B

Jordan, K

Deschauer, M

Zierz, S

机构：

[1] Univ Halle Wittenberg, Dept Neurol, D-06120 Halle, Germany

[2] Univ Halle Wittenberg, Dept Hematol Oncol, D-06120 Halle, Germany

来源：

MUSCLE & NERVE | 2006年 / 33卷 / 04期

关键词：

B lymphocytes; immunosuppression; MuSK antibodies; myas; thenia gravis; rituximab;

D O I：

10.1002/mus.20479

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We report on a 56-year-old woman with muscle-specific receptor tyrosine kinase (MuSK) anti body-positive myasthenia with predominant bulbar symptoms and respiratory insufficiency. Conventional immunosuppression (prednisolone, azathioprine, mycophenolate mofetil) could not maintain the clinical improvement initially achieved by repeated plasma exchanges. Therefore, treatment with rituximab was initiated. After 2 months of rituximab treatment, remarkable clinical improvement correlating with a reduction of MuSK serum antibodies was seen. The patient continued to remain remain stable 12 months after initiation of therapy. This case report demonstrates that rituximab may be an effective and tolerable treatment in MuSK anti body-positive myasthenia gravis.

引用

收藏

页码：575 / 580

页数：6

相关论文

共 30 条

[1] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

[2] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[3]

Charlton B, 1985, Trans Am Soc Artif Intern Organs, V31, P711

[4] Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis [J].

Evoli, A ;

Tonali, PA ;

Padua, L ;

Lo Monaco, M ;

Scuderi, F ;

Batocchi, AP ;

Marino, M ;

Bartoccioni, E .

BRAIN, 2003, 126 :2304-2311

[5] Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma [J].

Gajra, A ;

Vajpayee, N ;

Grethlein, SJ .

AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (02) :196-197

[6] Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule [J].

Ghielmini, M ;

Schmitz, SFH ;

Cogliatti, SB ;

Pichert, G ;

Hummerjohann, J ;

Waltzer, U ;

Fey, MF ;

Betticher, DC ;

Martinelli, G ;

Peccatori, F ;

Hess, U ;

Zucca, E ;

Stupp, R ;

Kovacsovics, T ;

Helg, C ;

Lohri, A ;

Bargetzi, M ;

Vorobiof, D ;

Cerny, T .

BLOOD, 2004, 103 (12) :4416-4423

[7] Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy [J].

Goldfarb, AR ;

Weimer, LH ;

Brannagan, TH .

MUSCLE & NERVE, 2005, 31 (04) :510-515

[8] Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies [J].

Hoch, W ;

McConville, J ;

Helms, S ;

Newsom-Davis, J ;

Melms, A ;

Vincent, A .

NATURE MEDICINE, 2001, 7 (03) :365-368

[9] MYASTHENIA-GRAVIS - REACTIVATION OF CLINICAL-DISEASE AND OF AUTOIMMUNE FACTORS AFTER DISCONTINUATION OF LONG-TERM AZATHIOPRINE [J].

HOHLFELD, R ;

TOYKA, KV ;

BESINGER, UA ;

GERHOLD, B ;

HEININGER, K .

ANNALS OF NEUROLOGY, 1985, 17 (03) :238-242

[10] Thymus changes in anti-MuSK-positive and -negative myasthenia gravis [J].

Lauriola, L ;

Ranelletti, F ;

Maggiano, N ;

Guerriero, M ;

Punzi, C ;

Marsili, F ;

Bartoccioni, E ;

Evoli, A .

NEUROLOGY, 2005, 64 (03) :536-538